GlassScriptPhysician profile
Brad M Dworkin
NPI 1528170362
$1,703.30
in general payments reported to CMS, 2019-2025
23 companies · $406 in 2025
The $406 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2021: $142 · 2022: $330 · 2023: $218 · 2024: $246 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.32 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $315.27 | 2019-2025 | Entyvio, Eohilia, Livtencity |
| Abbvie INC. | $296.41 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $219.91 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $156.48 | 2022-2024 | Zeposia |
| Covidien LP | $145.40 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Ardelyx, INC. | $62.20 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $40.56 | 2024-2025 | Zenpep |
| Genzyme Corporation | $39.74 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $39.54 | 2021 | |
| Madrigal Pharmaceuticals | $37.03 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $31.68 | 2025 | Iqirvo |
| Lilly USA, LLC | $31.56 | 2024 | Omvoh |
| Pfizer INC. | $30.84 | 2019 | |
| Qol Medical, LLC | $30.71 | 2025 | Sucraid |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.64 | 2022-2024 | Trulance |
| Ironwood Pharmaceuticals, INC | $22.47 | 2024 | |
| Phathom Pharmaceuticals, INC. | $21.32 | 2024 | Voquezna |
| Ferring Pharmaceuticals INC. | $20.90 | 2023 | Rebyota |
| Celltrion USA INC. | $20.22 | 2024 | Zymfentra |
| Fujifilm Healthcare Americas Corporation | $16.59 | 2025 | |
| Alnylam Pharmaceuticals INC. | $14.52 | 2025 | Givlaari |
| Amgen INC. | $13.82 | 2023 | Amjevita, Avsola |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Dworkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.